PASSAGE BIO INC
Passage Bio Inc (PASG) is a clinical-stage biotechnology company developing AAV-based gene therapies for rare monogenic central nervous system disorders. Investors should know the business is focused on scientific research and early-stage clinical development rather than current product sales, so revenue and profits are likely limited or non-existent. The company's small market capitalisation suggests limited liquidity and higher share-price volatility compared with larger peers. Key value drivers are clinical trial readouts, regulatory decisions and potential partnerships or licensing deals, all of which carry binary outcomes and long timelines. Development-stage biotechs often face substantial financing needs and dilution risk if they raise capital. For general education: this profile is not investment advice — gene therapy stocks can offer significant upside but also meaningful downside, and Passage Bio suits investors who understand biotech risk, can tolerate potential loss, and are prepared for a long investment horizon.
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying Passage Bio's stock with a target price of $7, indicating significant growth potential.
Financial Health
Passage Bio Inc shows strong cash flow and a solid book value per share, indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring PASG
Beyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: July 30, 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: July 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage catalyst watch
Clinical readouts and regulatory milestones can create sharp share-price moves, though outcomes are binary and performance can vary.
Rare disease focus
Concentrating on rare monogenic neurological disorders can mean high scientific value if successful, but small patient populations and regulatory hurdles add uncertainty.
High scientific risk
Gene therapy development is technically complex and capital-intensive; investors should expect dilution risk and long timelines.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.